• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2008     Canadian Agency for Drugs and Technologies in Health (CADTH) Polyclonal intravenous immunoglobulin in patients with immune thrombocytopenic purpura: clinical systematic review
2009     HAYES, Inc. Polyetheretherketone (PEEK) interbody cages for spinal fusion
2003     Adelaide Health Technology Assessment (AHTA) Polyheme (R) and hemopure (R), blood substitute products: for the provision of emergency, short-term transfusion to trauma patients
2012     Agenzia nazionale per i servizi sanitari regionali (Agenas) Polylactic-glycolic acid absorbable synthetic suture (Pgla) plus antibacterial: a systematic review
1995     University HealthSystem Consortium (UHC) Polymerase chain reaction
2007     HAYES, Inc. Polymerase chain reaction (PCR) molecular testing for diagnosis of group B streptococcal infection in newborns
2007     HAYES, Inc. Polymerase chain reaction (PCR)-based assays For methicillin-resistant staphylococcus aureus (MRSA) surveillance testing
2010     HAYES, Inc. Polymerase Chain Reaction (PCR)-based assays for rapid diagnosis of clostridium difficile in hospitalized patients
2003     Medical Services Advisory Committee (MSAC) Polymerase chain reaction in the diagnosis and monitoring of patients with AML1-ETO and CBF beta-MYH11 gene rearrangement in acute myeloid leukaemia
2004     Medical Services Advisory Committee (MSAC) Polymerase chain reaction in the diagnosis and monitoring of patients with BCR-ABL gene rearrangement in acute lymphoblastic leukaemia
2003     Medical Services Advisory Committee (MSAC) Polymerase chain reaction in the diagnosis and monitoring of patients with BCR-ABL gene rearrangement in chronic myeloid leukaemia
2003     Medical Services Advisory Committee (MSAC) Polymerase chain reaction in the diagnosis and monitoring of patients with PML-RAR alpha and PLZF-RAR alpha gene rearrangement in acute promyelocytic leukaemia
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Polymerase chain reaction tests for methicillin-resistant staphylococcus aureus in hospitalized patients: clinical and cost-effectiveness analyses
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Polypharmacological treatment of type 2 diabetes in daily clinical practice - primary research, conference
2006     Medical Advisory Secretariat (MAS) Polysomnography in patients with obstructive sleep apnea: an evidence-based analysis
2019     Belgian Health Care Knowledge Centre (KCE) Polyvalent immunoglobulins – Part 1: A rapid review
2020     Belgian Health Care Knowledge Centre (KCE) Polyvalent immunoglobulins – Part 2: use in Belgium
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pomalidomide (Imnovid®)
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pomalidomide (Pomalyst®) for the treatment of refractory multiple myeloma or relapsed and refractory multiple myeloma
2012     NIHR Horizon Scanning Centre (NIHR HSC) Pomalidomide for multiple myeloma – third line
2017     National Institute for Health and Care Excellence (NICE) Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib. NICE technology appraisal guidance 427
2019     National Institute for Health and Care Excellence (NICE) Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 602
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ponatinib (Iclusig) for chronic myeloid leukaemia
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ponatinib (Iclusig®)
2012     NIHR Horizon Scanning Centre (NIHR HSC) Ponatinib for chronic myeloid leukaemia or Ph+ acute lymphoblastic leukaemia
2017     National Institute for Health and Care Excellence (NICE) Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. NICE technology appraisal guidance 451
2022     National Institute for Health and Care Excellence (NICE) Ponesimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 767
2009     HAYES, Inc. Pooled human thrombin or recombinant human thrombin versus bovine thrombin for surgical hemostasis
2003     Adelaide Health Technology Assessment (AHTA) Population genetic screening for haemochromatosis: identifying asymptomatic "at risk" homozygous individuals
2012     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: accelerated repeat screening for bowel cancer
2013     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: bowel cancer screening by pill camera
2013     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: calcium score and the risk of cardiovascular disease
2013     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: Continuing a population screening trial
2014     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: first trimester scan for prenatal screening
2013     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: mammography in two directions as standard
2013     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: national population screening programme for bowel cancer
2013     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: noninvasive prenatal test for increased risk of trisomy
2011     Health Council of the Netherlands Gezondheidsraad (GR) Population screening act: prostate cancer screening using MRI
2015     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: risk stratification based on familial risk of bowel cancer
2014     Health Council of the Netherlands Gezondheidsraad (GR) Population screening act: study into self-sampling as primary screening for cervical cancer
2015     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: study of faecal tests within the population based screening programme for colorectal cancer
2012     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: tuberculosis screening
2014     Health Council of the Netherlands Gezondheidsraad (GR) Population screening for breast cancer: expectations and developments
2007     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) Population screening for primary open-angle glaucoma
2008     University of York Population tobacco control interventions and their effects on social inequalities in smoking
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Population-based colorectal cancer screening: guidelines
2010     Medical Advisory Secretariat (MAS) Population-based strategies for smoking cessation
2015     NIHR Public Health Research (PHR) programme Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE)
2003     NIHR Horizon Scanning Centre (NIHR HSC) Porfimer sodium photodynamic therapy for high-grade dysplasia of Barrett's oesophagus - horizon scanning review
2010     Quality Improvement Scotland (NHS QIS ) Portable bladder ultrasound scanners
2006     Medical Advisory Secretariat (MAS) Portable bladder ultrasound: an evidence-based analysis
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable bone mineral density scanners: a review of the clinical effectiveness
2003     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment
2010     Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Portable computed tomography (CT) for the study of diagnostic imaging in specialised areas or setting
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Portable home hemodialysis
2007     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable home hemodialysis for kidney failure
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable monitoring devices for diagnosis of obstructive sleep apnea at home: review of accuracy, cost effectiveness, guidelines, and coverage in Canada
2020     Ontario Health Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment
2014     HAYES, Inc. Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable ultrasonography in small emergency departments: a systematic review of the guidelines and clinical-effectiveness
2003     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Portable ultrasound - systematic review, expert panel
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable ultrasound devices for obstetrical or prenatal assessment in rural or remote settings: a review of the diagnostic accuracy
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Portable ultrasound devices in emergency departments
2018     Health Quality Ontario (HQO) Portable ultraviolet light surface-disinfecting devices for prevention of hospital-acquired infections: a healthtechnology assessment
2018     Health Quality Ontario (HQO) Portable ultraviolet light surface-disinfecting devices for prevention of hospital-acquired infections: OHTAC recommendation
2014     HAYES, Inc. Portable versus non-portable intermittent pneumatic compression for prevention of postoperative deep vein thrombosis
2011     HAYES, Inc. Portal vein embolization for liver regeneration followed by staged hepatectomy for cholangiocarcinoma
2011     HAYES, Inc. Portal vein embolization for liver regeneration followed by staged hepatectomy for cholangiocarcinoma
2015     Health Quality Ontario (HQO) Positional Magnetic Resonance Imaging for people with Ehlers-Danlos Syndrome or suspected craniovertebral or cervical spine abnormalities: an evidence-based analysis
2015     Health Quality Ontario (HQO) Positional magnetic resonance imaging for people with Ehlers-Danlos syndrome or suspected craniovertebral or cervical spine abnormalities: OHTAC recommendation
2018     NIHR Health Technology Assessment programme Positive behaviour support training for staff for treating challenging behaviour in people with intellectual disabilities: a cluster RCT
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Positive expiratory pressure devices and incentive spirometers for the prevention of pneumonia: comparative clinical effectiveness and guidelines
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Positive versus negative needleless connectors for central venous lines and peripheral lines: a review of the clinical effectiveness and guidelines
2004     Agency for Healthcare Research and Quality (AHRQ) Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular)
1996     VA Technology Assessment Program (VATAP) Positron emission tomography
2001     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Positron emission tomography
2000     Medical Services Advisory Committee (MSAC) Positron emission tomography
1994     University HealthSystem Consortium (UHC) Positron emission tomography
2001     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Positron emission tomography - the economic efficacy
2000     Hannover Medical School, Medizinische Hochschule Hannover (MHH) Positron emission tomography - the economic efficacy
2001     Agency for Healthcare Research and Quality (AHRQ) Positron emission tomography (FDG) for myocardial viability
2002     Agency for Healthcare Research and Quality (AHRQ) Positron emission tomography (FDG) for soft tissue sarcoma
2000     Norwegian Knowledge Centre for the Health Services (NOKC) Positron emission tomography (PET)
2003     Norwegian Knowledge Centre for the Health Services (NOKC) Positron emission tomography (PET) - diagnostic and clinical use
2003     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Positron emission tomography (PET) - systematic review of efficacy in selective medical indications
2003     Hannover Medical School, Medizinische Hochschule Hannover (MHH) Positron emission tomography (PET) - systematic review of efficacy in selective medical indications
2011     HAYES, Inc. Positron Emission Tomography (PET) and Combined Positron Emission Tomography-Computed Tomography (PET-CT) for diagnosis and management of soft tissue sarcoma
2013     HAYES, Inc. Positron Emission Tomography (PET) and Combined Positron Emission Tomography-Computed Tomography (PET-CT) for the posttreatment management of cancer of the head and neck
2010     HAYES, Inc. Positron emission tomography (PET) and combined positron emission tomography-computed tomography (PET-CT) for breast cancer detection
2011     HAYES, Inc. Positron Emission Tomography (PET) and Combined Positron Emission Tomography-Computed Tomography (PET-CT) for detection of recurrent ovarian cancer
2011     HAYES, Inc. Positron Emission Tomography (PET) and combined Positron Emission Tomography-Computed Tomography (PET-CT) for diagnosis and initial staging of ovarian cancer
2011     NIHR Health Technology Assessment programme Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation
2017     HAYES, Inc. Positron Emission Tomography (PET) for Alzheimer disease
2016     HAYES, Inc. Positron Emission Tomography (PET) for Alzheimer disease
2011     HAYES, Inc. Positron Emission Tomography (PET) for alzheimer's disease
2002     HAYES, Inc. Positron emission tomography (PET) for Alzheimer's disease (AD)
2007     HAYES, Inc. Positron emission tomography (PET) for alzheimer's disease (AD)
2005     HAYES, Inc. Positron emission tomography (PET) for assessing myocardial metabolism
2002     HAYES, Inc. Positron emission tomography (PET) for bone cancer